CIV chemotherapy
Phase 2Small molecule
CIV chemotherapy is one of 32 small molecule programs targeting Rhabdomyosarcoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Rhabdomyosarcoma
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Verzenio
Eli LillyApproved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Camptosar
PfizerPhase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Cosmegen
RRECORDATI GROUP
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rhabdomyosarcoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CIV chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details